Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qiagen NV's Operating Income for the
three
months ended in Mar. 2026 was €101 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €440 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Qiagen NV's Operating Income for the
three
months ended in Mar. 2026 was €101 Mil. Qiagen NV's Revenue for the
three
months ended in Mar. 2026 was €426 Mil. Therefore, Qiagen NV's Operating Margin % for the quarter that ended in Mar. 2026 was 23.69%.
Warning Sign:
Qiagen NV operating margin has been in a 5-year decline. The average rate of decline per year is -11%.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Qiagen NV's annualizedROC % for the quarter that ended in Mar. 2026 was 7.81%.
Qiagen NV's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 28.87%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Qiagen NV Operating Income Related Terms
Qiagen NV Operating Income Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €440 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (LTS:0RLT) has a Operating Income of €440 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Qiagen NV and its competitors.
Is Qiagen NV's Operating Income too high?
Qiagen NV's current Operating Income is €440 Mil. Overall, Qiagen NV has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Operating Income compare to CRL and BLLN?
Qiagen NV's Operating Income of €440 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Diagnostics & Research company?
A good Operating Income depends on the Medical Diagnostics & Research industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Qiagen NV and its competitors. Qiagen NV's current Operating Income is €440 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (LTS:0RLT) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.48, compared to a current price of €35.73 — trading 21.4% below its estimated fair value. The current Operating Income is €440 Mil. Qiagen NV's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Qiagen NV (LTS:0RLT), the current Operating Income is €440 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (LTS:0RLT) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €35.73 is trading 21.4% below its estimated GF Value™ of €45.48.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for LTS:0RLT:
Operating Income: €440 Mil
GF Value™: €45.48 vs. price of €35.73 (21.4% below fair value)
No single metric tells the full story. See the LTS:0RLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
68GF Score
Get the complete analysis for LTS:0RLT
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RLT has been successfully added to your 
